Need a report that reflects how COVID-19 has impacted this market and its growth?
The Japan Diagnostic Imaging Market is projected to register a CAGR of 6.28% over the forecast period (2022-2027).
The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. However, with the advent of the COVID-19 infection, lung imaging became a major part of COVID-19 diagnostics, as it helped diagnose the severity of the disease in the affected population. For instance, an article titled “Computed tomography surveillance helps tracking COVID-19 outbreak” published in the Japanese Journal of Radiology in December 2020 indicated that a computed tomography surveillance program (CT-surveillance) could demonstrate the epidemiologic features of COVID-19 infection. Such activities helped the growth of the market during the COVID-19 pandemic.
The major factors augmenting the growth of the diagnostic imaging market in Japan include the rise in the prevalence of chronic diseases, increased adoption of advanced technologies in medical imaging, and the rise in the geriatric population.
According to the Statistics Bureau of Japan, the country is experiencing a “super-aging” society both in rural and urban areas. As per the February 2021 article by the Public Relations Office of the Government of Japan, the percentage of people over the age of 65 years old in Japan is expected to reach 33.3% by the year 2036 and 38.4% by the year 2065. Moreover, the prevalence of chronic diseases is also increasing among the Japanese population, and more so among the geriatric population as they are more prone to diseases. But Japan is a developed country that has a developed healthcare system as well. The healthcare industry in Japan has well adopted new innovations and advancements for diagnosis. These factors have helped this diagnostic imaging market grow in Japan.
An article titled “Developing diagnostic reference levels in Japan” published in the Japanese Journal of Radiology in November 2021 indicated that the use of radiological tests in the nation has been increasing significantly in recent years. The article also aimed at developing an infrastructure for the review of diagnostic references in the nation. Such activities are likely to propel the growth of the market over the forecast period.
However, the cost of diagnosis due to expensive instruments and side effects that follow the diagnostic imaging have been restraining the growth of this market.
Scope of the Report
As per the scope of the report, the diagnostic imaging market covers a wide array of medical devices used for diagnostic purposes. In the report, a detailed analysis of the diagnostic imaging market in Japan is provided. The market is segmented by Modality (MRI, Computed Tomography, Ultrasound, X-Ray, Nuclear Imaging, Fluoroscopy, and Mammography), Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, and Other Applications), and End-user (Hospitals, Diagnostic Centers and Others). The report offers the value (in USD million) for the above segments.
|By End User|
Key Market Trends
Oncology Segment is expected to Account for Largest Market Share during the Forecast Period
The oncology segment is expected to have significant growth in the nation, owing to the rising cancer cases, and increasing technological innovations in the image diagnostics segment.
According to the Globocan 2020 report, an estimate of around 1.03 million people in Japan were affected by cancer. The large number of population affected by cancer in the nation, increases the demand for the proper diagnostics of the disease for the healthcare providers to provide the proper surgical or non-surgical treatment. Thus, the rise in the demand for the clinical diagnostic imaging is expected to boost the growth of the diagnostic imaging market in Japan over the forecast period.
Diagnostic imaging plays a vital role in interventional oncology (with rising opportunities to diagnose and treat in a targeted and minimally or non-invasive manner) as well as in chemo and radiation therapy. Tools, such as CT, are the highly beneficial and preferred method of imaging for many conditions, including trauma patients. Comparatively, PET is mostly preferred as compared to SPECT, and there are hybrid medical devices also available such as PET/CT or PET/MRI.
Several key market players focusing on the diagnostic imaging in Japan are also aiding the growth of the market. For instance, in July 2020, Philips announced the launch of its Lumify handheld ultrasound solution in Japan. Lumify is a highly versatile solution primarily intended for use in places where quick and easy access to diagnostic ultrasound imaging is required. Such product launches are propelling the growth of the market.
As Japan has a developed healthcare system, these technologies have been implemented into the routine and have been helping the patients and physicians as well. Hence, an increased prevalence of cancer and the implementation of new technologies are expected to help this segment dominate the market.
To understand key trends, Download Sample Report
Japan has been an attractive market for domestic and international players as well. The leading vendors in the market are launching advanced diagnostic imaging equipment. These companies have also been involved in the acquisition of related healthcare companies, in order to improve their product portfolio, geographical presence, and growth. By incorporating the acquired technologies, the companies are driving product innovation.
Canon Medical Systems Corporation
- In June 2022, Konica Minolta, Inc. released DDRAtlas Ver. 1.0, which records normal cases, as the first part of Dynamic Digital Radiography DDRAtlas on its membership website in Japan.
- In April 2022, Clairvo Technologies obtained market authorization for VIDA Insights, an image analysis software to assist in the reading of chest CT images developed by VIDA Diagnostics Inc. in accordance with the Pharmaceutical and Medical Device Act.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing geriatric poulation
4.2.2 Increased adoption of diagnostic imaging by the medical industry
4.2.3 Technological advances and rapid innovation
4.2.4 Increased incidence of chronic diseases
4.3 Market Restraints
4.3.1 Expensive procedures and equipment
4.3.2 Side effects of diagnostic imaging procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
5.1 By Modality
5.1.2 Computed Tomography
5.1.5 Nuclear Imaging
5.2 By Application
5.2.7 Other Applications
5.3 By End User
5.3.2 Diagnostic Centers
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Canon Medical Systems Corporation
6.1.2 Carestream Health, Inc.
6.1.3 Esaote SpA
6.1.4 Fujifilm Holdings
6.1.5 GE Healthcare
6.1.6 Hitachi Medical Corporation
6.1.7 Hologic, Inc.
6.1.8 Philips Healthcare
6.1.9 Shimadzu Corporation
6.1.10 Siemens Healthcare
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Japan Diagnostic Imaging Market market is studied from 2019 - 2027.
What is the growth rate of Japan Diagnostic Imaging Market?
The Japan Diagnostic Imaging Market is growing at a CAGR of 6.28% over the next 5 years.
Who are the key players in Japan Diagnostic Imaging Market?
Canon Medical Systems Corporation, Fujifilm Holdings, GE Healthcare, Philips Healthcare, Siemens Healthcare are the major companies operating in Japan Diagnostic Imaging Market.